0001225208-23-002038.txt : 20230215
0001225208-23-002038.hdr.sgml : 20230215
20230215174402
ACCESSION NUMBER: 0001225208-23-002038
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230214
FILED AS OF DATE: 20230215
DATE AS OF CHANGE: 20230215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mirviss Jeffrey B.
CENTRAL INDEX KEY: 0001566094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 23636548
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
4
1
doc4.xml
X0306
4
2023-02-14
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001566094
Mirviss Jeffrey B.
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
EVP&Pres, Periph Intervent
Performance Share Units
2023-02-14
4
A
0
10430.0000
0.0000
A
2024-12-31
2024-12-31
Common Stock
10430.0000
10430.0000
D
Restricted Stock Units
2023-02-14
4
A
0
11104.0000
0.0000
A
2027-02-14
Common Stock
11104.0000
11104.0000
D
Stock Option (Right to Buy)
47.2800
2023-02-14
4
A
0
28893.0000
0.0000
A
2033-02-14
Common Stock
28893.0000
28893.0000
D
Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024.
Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
/s/ Susan Thompson, Attorney-in-Fact
2023-02-15